Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia

ABSTRACT The recombinant human keratinocyte growth factor, palifermin, offers a potential means of reducing or preventing mucositis in patient undergoing intensive cancer treatments. This case report details the development of acral erythrodysaesthesia in one patient who underwent palifermin treatme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Australasian journal of dermatology 2011-02, Vol.52 (1), p.59-61
Hauptverfasser:	Milne, Olivia, Cutts, Briony, McLean, Catriona, Gin, Douglas
Format:	Artikel
Sprache:	eng
Schlagworte:	acral erythema acral erythrodysesthesia adverse reaction Biological and medical sciences cutaneous reaction Dermatology drug reaction Fibroblast Growth Factor 7 - adverse effects hand-foot syndrome Hematologic and hematopoietic diseases human keratinocyte growth factor Humans Leukemia, Myeloid, Acute - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences palifermin palmar plantar syndrome Paresthesia - chemically induced Paresthesia - pathology Recombinant Proteins - adverse effects Skin involvement in other diseases. Miscellaneous. General aspects toxic erythema of palms and soles Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACT The recombinant human keratinocyte growth factor, palifermin, offers a potential means of reducing or preventing mucositis in patient undergoing intensive cancer treatments. This case report details the development of acral erythrodysaesthesia in one patient who underwent palifermin treatment prior to high‐intensity re‐induction chemotherapy for acute myeloid leukaemia.
ISSN:	0004-8380 1440-0960
DOI:	10.1111/j.1440-0960.2010.00682.x